IVA
Inventiva S.A.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-54.97
P/S
39.92
EV/EBITDA
-2.79
DCF Value
$-9.17
FCF Yield
-21.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
86.4%
Operating Margin
-621.0%
Net Margin
-1891.7%
ROE
536.4%
ROA
-174.3%
ROIC
-80.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $4.5M | $-175.9M | $-1.62 |
| Q4 2024 | $6.5M | $-135.2M | $-2.60 |
| FY 2024 | $9.2M | $-184.2M | $-3.54 |
| Q2 2024 | $2.7M | $-49.0M | $-0.94 |
Analyst Ratings
View AllCompany Info
Sector
Healthcare
Industry
—
Country
FR
Exchange
NASDAQ
Beta
0.92
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.